Tubulis GmbH Email Format
Biotechnology ResearchBavaria, Germany51-200 Employees
Tubulis GmbH operates in biotechnology research and concentrates on creating protein-drug conjugates that are uniquely matched to disease biology. The company combines proprietary technologies with disease-specific biology to broaden the therapeutic potential of antibody-drug conjugates. Its goal is to improve patient outcomes by expanding the range of conditions that ADCs can address. Tubulis pursues development of a broad pipeline, leveraging its own discovery capabilities and collaborating with partners who possess antibody and chemical assets to solve development challenges. Based in Munich, Bavaria, Germany, Tubulis is a mid-sized biotechnology company that originated as a spin-off from LMU Munich and the Leibniz Institute for Molecular Pharmacology. In 2025 the company advanced its lead ADC candidate, TUB-040, and presented Phase I/IIa data at ESMO 2025.